The article discusses the use of glucocorticoids in the treatment of community-acquired pneumonia in an African setting. A pragmatic randomized trial in Kenya included 2,180 adult patients with pneumonia who were randomly assigned to receive standard care or standard care plus 10 days of low-dose glucocorticoid therapy. The results showed that the addition of glucocorticoids reduced mortality by 16% compared to standard treatment alone. The study was conducted in 18 public hospitals and the results are relevant to resource-limited settings. Glucocorticoids are a cheap and available treatment, but they can cause hyperglycemia, which is problematic in hospitals with inadequate blood sugar monitoring. The authors warn that the benefits of treatment must be balanced against the risk of metabolic complications, especially with the increasing prevalence of diabetes in Africa. The results confirm that glucocorticoids can reduce pneumonia mortality even in low-income areas.